InflaRx N.V. (IFRX) Stock
IFRX Key Statistics
About InflaRx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
CEO: Niels C. Riedemann. Company website
IFRX — Frequently Asked Questions
What is the IFRX stock price today?
InflaRx N.V. (IFRX) trades at $2.78, up 41.17% on the day, as of Sep 20, 2026 15:00 UTC.
What is InflaRx N.V.'s market cap?
InflaRx N.V. has a market capitalisation of $201.05M, calculated from the live IFRX share price and shares outstanding.
What is the P/E ratio of IFRX?
IFRX has no meaningful price-to-earnings ratio: InflaRx N.V. lost $0.66 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does InflaRx N.V. make?
InflaRx N.V. generated revenue of $28,173.00 over the trailing twelve months, which puts the stock at 7,136.40 times sales.
What is the 52-week range for IFRX?
IFRX has traded between $0.80 and $2.81 over the past 52 weeks, and the last price is 1.0% below that high.
Is InflaRx N.V. profitable?
No. InflaRx N.V. is loss-making, with a net margin of -9,999.99% over the trailing twelve months.
What is the analyst price target for IFRX?
Wall Street analysts rate IFRX Buy, with an average price target of $2.00, 28.1% below the current price.
What sector is InflaRx N.V. in?
InflaRx N.V. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in DE .
Who is the CEO of InflaRx N.V.?
Niels C. Riedemann is the chief executive of InflaRx N.V., which employs 74 people.
Where can I track IFRX in real time?
QFI Terminal shows IFRX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See IFRX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open IFRX in Terminal See plans